实现粪便微生物群移植的潜力

The Prescriber Pub Date : 2023-02-01 DOI:10.1002/psb.2043

Angela Dowden

{"title":"实现粪便微生物群移植的潜力","authors":"Angela Dowden","doi":"10.1002/psb.2043","DOIUrl":null,"url":null,"abstract":"First reported in Western medical literature in the 1950s, faecal microbiota transplant (FMT) has now come of age as a cost‐effective treatment for recurrent Clostridioides difficile infection. But what do we know about FMT, what are its uses and limitations, and where might microbiome treatments take us in the future?","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"49 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Realising the potential of faecal microbiota transplant\",\"authors\":\"Angela Dowden\",\"doi\":\"10.1002/psb.2043\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"First reported in Western medical literature in the 1950s, faecal microbiota transplant (FMT) has now come of age as a cost‐effective treatment for recurrent Clostridioides difficile infection. But what do we know about FMT, what are its uses and limitations, and where might microbiome treatments take us in the future?\",\"PeriodicalId\":88184,\"journal\":{\"name\":\"The Prescriber\",\"volume\":\"49 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/psb.2043\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/psb.2043","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

20世纪50年代首次在西方医学文献中报道，粪便微生物群移植(FMT)现在已经成为治疗复发性艰难梭菌感染的一种经济有效的治疗方法。但是我们对FMT了解多少，它的用途和局限性是什么，以及微生物组治疗在未来会把我们带到哪里?

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Realising the potential of faecal microbiota transplant

First reported in Western medical literature in the 1950s, faecal microbiota transplant (FMT) has now come of age as a cost‐effective treatment for recurrent Clostridioides difficile infection. But what do we know about FMT, what are its uses and limitations, and where might microbiome treatments take us in the future?

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The Prescriber

自引率

0.00%

发文量